Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.

The game is afoot in the obesity space as GLP-1 rivals Eli Lilly and Novo Nordisk take their showdown to a new level. Lilly ...

Shares of CVS Health Corp. CVS soared toward a one-year ... Obamacare business and will increase access to weight-loss drug Wegovy as it reported blowout earnings. The company said it decided ...

The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

NRx stock has fallen over 2.8% this year. CVS Health Corp. (CVS) (+650% Weekly Message Volume) The health solutions giant ...

The early results for stop-loss claims, or claims for catastrophic losses, are in line with the insurer's expectations, ...